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The effectiveness of intensive surveillance in women at high risk for breast cancer due to a familial or genetic predisposition is
uncertain and is currently being evaluated in a Dutch magnetic resonance imaging (MRI) screening (MRISC) study, in which annual
imaging consists of mammography and MRI. Unfavourable side effects on health-related quality of life may arise from this screening
process. We examined the short-term effects of screening for breast cancer in high-risk women on generic health-related quality of
life and distress. A total of 519 participants in the MRISC study were asked to complete generic health-status questionnaires (SF-36,
EQ-5D) as well as additional questionnaires for distress and items relating to breast cancer screening, at three different time points
around screening. The study population showed significantly better generic health-related quality of life scores compared to age-/sex-
adjusted reference scores from the general population. Neither generic health-related quality of life scores nor distress scores among
the study sample (n¼334) showed significant changes over time. The impact of the screening process on generic health status did
not differ between risk categories. Relatively more women reported mammography as quite to very painful (30.1%) compared to
MRI. Anxiety was experienced by 37% of the women undergoing MRI. We conclude that screening for breast cancer in high-risk
women does not have an unfavourable impact on short-term generic health-related quality of life and general distress. In this study,
high-risk women who opted for regular breast cancer screening had a better health status than women from the general population.
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Women in Western countries have a 8–10% average lifetime risk
of developing breast cancer. One of the risk-increasing factors is a
family history of breast cancer (Claus et al, 1991; Peto et al, 1996).
About 5–10% of all breast cancer cases occur in women with a
strong family history, and in the Netherlands approximately 25%
of these cases may be attributed to the BRCA1 and BRCA2 breast
cancer susceptibility gene mutations (Verhoog et al, 2001). Several
strategies to reduce the risk of breast cancer or breast cancer death
may be discussed with BRCA 1/2 mutation carriers and women
with a strong family history, such as intensive surveillance,
chemoprevention (Cuzick et al, 2003) and prophylactic mastect-
omy (Meijers-Heijboer et al, 2001). Guidelines for surveillance of
these women mostly consist of biannual clinical breast examina-
tion (CBE), annual mammography and recommendation for
monthly breast self-examination (BSE) (Vasen et al, 1998).
Alternative imaging techniques like magnetic resonance imaging
(MRI) may be useful because of reported high sensitivity in a
diagnostic setting (Heywang-Kobrunner et al, 1997; Friedrich,
1998).
The effectiveness of intensive surveillance in women at high risk
for breast cancer is yet uncertain, although preliminary results
have been reported (Kuhl et al, 2000; Brekelmans et al, 2001;
Stoutjesdijk et al, 2001; Warner et al, 2001; Kriege et al, 2003). It is
currently being evaluated as part of a large ongoing prospective
national MRI screening (MRISC) study in the Netherlands, in
which annual imaging consists of mammography and MRI (Kriege
et al, 2001). Unfavourable side effects on health-related quality of
life (or health status) may arise from the process of screening itself,
like pain, discomfort and feelings of anxiety and distress. Several
studies have shown that women with normal results after
mammography screening experience no important negative
psychological consequences, whereas recall because of a false-
positive mammogram causes adverse emotional, physical and
social effects (Lerman et al, 1991; Cockburn et al, 1994; Sutton et al,
1995; Gilbert et al, 1998). Only one study reported that screening
appeared to be less stressful for women with a family history than
for those without (Gilbert et al, 1998).
This article describes the short-term effects of screening for
breast cancer in high-risk women on health-related quality of life,
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lby empirical assessment at various stages in the screening process.
It addresses two specific questions: (1) Does the screening process
have any impact, negative or positive, on generic health-related
quality of life and distress among high-risk women? (2) Do high-
risk women who opt for regular screening differ from the general
population with respect to generic health-related quality of life?
MATERIALS AND METHODS
MRISC study
The MRISC study, activated at six family cancer clinics in the
Netherlands, is an ongoing prospective observational study for
women at increased risk for breast cancer due to a familial or
genetic predisposition (Kriege et al, 2001). The study was designed
to investigate the effectiveness of intensive surveillance and the
value of MRI compared to mammography as a screening tool in
high-risk women. Women who were already under intensive
surveillance and women who came for the first time to the family
cancer clinic were asked to participate in the MRISC study.
Women with evident symptoms suspicious for breast cancer or
previous breast cancer were excluded. Participants visited the
family cancer clinic twice a year for surveillance, consisting of
biannual CBE and annual mammography and MRI. All women got
instructions for monthly BSE. Since the start of the study in 1999,
1952 women have been included. The first results were recently
presented (Kriege et al, 2003). Approval for the MRISC study was
obtained from the Medical Ethical Committees of all six
participating family cancer clinics. The health-related quality of
life study was approved by the Medical Ethical Committee of the
Erasmus MC, University Medical Center Rotterdam.
Design of the study on health-status effects of screening
high-risk women
Participants in the MRISC study who were under surveillance at
the Family Cancer Clinic of the Erasmus MC, Daniel den Hoed
Cancer Center were approached for the empirical health-status
study either by mail or by their physician at a scheduled visit at the
family cancer clinic. Women received written information about
the study, including an informed consent form and a form on
which they could indicate that they did not want to participate.
Women could send the appropriate form back in a reply paid
envelope. A reminder letter was sent to those women who did not
return any form within 4 months.
Health-status data were collected at the time points outlined in
Figure 1. At 2 months prior to the scheduled screening visit
(consisting of either CBE alone or CBE in combination with
mammography and MRI) participating women received their first
(baseline) questionnaire (time 0 or T0) by mail. They were
requested to fill it in and send it back within 2 weeks. The second
assessment (time 1 or T1) took place at the day of the scheduled
screening visit, preceding the screening. Postscreening measure-
ment (time 2 or T2) was performed 1 week (in case of CBE alone)
or 4 weeks (in case of CBE in combination with mammography
and MRI) after screening. By that time all women had been
informed whether they had breast cancer or not, including those
who received additional diagnostic evaluation after scheduled
screening. Women with a screen-detected or interval breast cancer
did not receive any questionnaire after the diagnosis. Women who
did not return their questionnaire within 4 weeks were sent a
reminder.
Health-status measures
Health-related quality of life was defined as the woman’s
functioning in physical, psychological and social domains. The
questionnaire contained the Medical Outcomes Study 36-Item
Short Form (SF-36) (Ware and Sherbourne, 1992; Ware et al, 1994;
Aaronson et al, 1998) as a generic health profile measure and the
EQ-5D as a generic preference-based measure of health-related
quality of life (Brooks, 1996; Dolan, 1997). In addition it contained
the somatic subscale (SOM) of the Symptom Checklist-90 (SCL-90)
(Derogatis, 1977), self-developed screen-specific items (Essink-Bot
et al, 1998) and other measures (to be reported elsewhere). We
used both the SOM scale and the role-emotional and mental health
Figure 1 Flow chart describing the number of questionnaires available for statistical analysis (cutoff point November 2002).
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lscales of the SF-36 as measures for distress. In the screen-specific
items, women were retrospectively (at T2) asked to grade the pain,
discomfort and anxiety experienced during CBE, mammography
and MRI. For further details on the health-status measures, we
refer to Appendix A.
Finally, the questionnaire contained items on sociodemographic
characteristics (including age, marital status, living status (single
or together), parity, educational level and employment status) and
cancer-related characteristics (the number of years adhering to
regular surveillance, frequency of BSE, benign breast symptoms in
the past, diagnosis of different type(s) of cancer in the past and
family history (mother and/or sister(s) affected with breast
cancer)).
Subgroups
Participating women were divided into subgroups according to
three criteria. The first was their cumulative lifetime risk (CLTR)
for developing breast cancer, based on the tables of Claus (Claus
et al, 1994) and additional information about the family history of
ovarian cancer (Kriege et al, 2001). Risk category 1 consisted of
BRCA 1/2 mutation carriers (50–85% CLTR), category 2 being
women with high risk for breast cancer (30–50% CLTR) and
category 3 comprising women with moderate risk for breast cancer
(15–30% CLTR). We also distinguished subgroups according to
screening modality (two subgroups: CBE alone or CBE in
combination with mammography and MRI) and additional
diagnostic evaluation after the scheduled screening (two sub-
groups: yes or no).
Statistical analysis
Missing values for the SF-36 items were imputed according to the
standard guidelines (Ware et al, 1993). No imputation of missing
values was applied to the rest of the variables.
Differences in distribution of background variables between the
different subgroups were analysed by means of the w
2 test, Fisher’s
exact test or linear-by-linear association (nominal and ordinal
variables), Student’s t-test or ANOVA (continuous variables with
normal distribution) and by nonparametric procedures (contin-
uous variables without normal distribution: Mann–Whitney or
Kruskal–Wallis test). Age- and sex-adjusted reference scores for
the SF-36 and EQ-5D were assigned to participating women at T0,
based on their age at T0. The one-sample t-test was used to test
whether the difference between the reference and the observed
health-related quality of life scores differed systematically from
zero. As only sex- and no age-adjusted reference scores for the
SOM scale were available, we analysed the differences between
observed SOM scale scores and sex-adjusted reference scores by
means of a t-test for two independent samples allowing for unequal
variances.
To evaluate changes over time in generic health-related quality
of life scores (SF-36 and EQ-5D) and in SOM scale scores for the
total group of women, we used a repeated measures ANOVA model
with time as the only main effect. Differences in health-related
quality of life and SOM scale scores between the various
subgroups, including differences over time, were also examined
with repeated measures ANOVA models. Three models were fitted,
each including the main effect for time, and one of the three
factors: risk category (model A), screening modality (model B) and
additional diagnostic evaluation (model C); all models included the
interaction effect for time with one of the three factors. For each
model, selection of relevant confounders was done by initially
including age and those background variables (Table 1) with a
significant (Pp0.10) difference in distribution between the
relevant subgroups as covariates in the model, and then by
removing covariates that did not show a significant (Pp0.05)
confounding effect on any of the outcome scores between the
subgroups. In all models, we used a compound symmetry
covariance structure. The parameters of these covariance matrices
were allowed to differ between groups in the models that included
one of the three group factors, as this provided for better fitting
models.
All P-values resulted from the use of two-sided statistical tests.
The data analyses were performed using SPSS (SPSS 10.0.7 for
Windows; SPSS Inc., Chicago, IL, USA) or the MIXED procedure of
SAS (SAS 8.00 TS Level 00M0 for Windows; SAS Institute Inc.,
Cary, NC, USA).
RESULTS
Characteristics of the study group
From September 2000 to November 2002, 519 women were
approached for the health-status study; 69.6% consented to
participate (Figure 1). At November 2002, we had 329 (T0), 316
(T1) and 288 (T2) completed and evaluable questionnaires.
Response rates were high among those who received a ques-
tionnaire (T0: 98.5%; T1: 96.6%; T2: 94.4%).
Sociodemographic and cancer-related background characteris-
tics of the total study sample and the different subgroups are given
in Table 1. The mean age at entry in the study was 40.9 years; 72%
of the women had a low to intermediate level of education. The
mean number of years already adhering to regular surveillance was
5.4 years, but this differed significantly (Pp0.01) between the three
risk categories. Of the total study sample, 1.6% just started with
regular surveillance. Most of the women (88.6%) had (had) a
mother and/or sister(s) affected with breast cancer.
No significant differences with regard to age (P¼0.38) and
CLTR of developing breast cancer (P¼0.36) were found between
the study sample (n¼334) and the women who refrained from
participation in the health-status study (n¼109). There were also
no significant differences with regard to sociodemographic and
cancer-related background characteristics and baseline SF-36, EQ-
5D and SOM scale scores between the 288 women with a usable T2
questionnaire and the 46 women (334–288) without a usable T2
questionnaire, except for the vitality score of the SF-36, which was
lower for the women without a usable T2 questionnaire (68.1 vs
60.3, Pp0.05).
Health-related quality of life over time
The mean score results from the SF-36, EQ-5D and SOM scale at
different time points around screening (T0, T1 and T2) are shown
in Table 2. For the total group of women, there was a significant
(Pp0.01) but small change in visual analogue scale (VAS) scores
over time. A post hoc analysis revealed that the mean VAS score at
T0 (81.9) differed significantly (Pp0.01) from the mean T1 score
(79.0), which in itself differed significantly (Pp0.05) from the
mean T2 score (80.7). All other generic health-related quality of life
scores (SF-36 and EQ-5D utility) and SOM scale scores did not
show any significant change over time.
High-risk women showed significantly (Pp0.01/Pp0.05) higher
SF-36 scores on most scales as compared to the age- and sex-
adjusted SF-36 reference scores from the Dutch (Aaronson et al,
1998) and USA (Ware et al, 1993, 1994) general population
(Table 2). Also, observed EQ-5D utilities and SOM scale scores
among our study sample were significantly (Pp0.01) more
favourable compared to the age- and sex-adjusted EQ-5D utility
reference scores from the Swedish general population (Burstro ¨m,
2003) and sex-adjusted SOM scale reference scores from the Dutch
general population (Arrindell and Ettema, 1986). Observed VAS
scores among our study sample were significantly lower (Pp0.01)
compared to the age- and sex-adjusted reference scores from the
Swedish general population (Burstro ¨m, 2003).
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subgroups over time
Covariates included in the final repeated measures ANOVA models
were age (models A, B and C), educational level (model B), number
of years adhering to regular surveillance (models A and B),
frequency of BSE (model A) and mother and/or sister(s) affected
with breast cancer (models A and B).
The analyses with model A revealed no significant interaction
between risk category and time (P-value range 0.16–0.73) for any
of the SF-36, EQ-5D and SOM scales. For none of these scales there
was a significant main effect of risk category (P-value range 0.12–
1.00). The same holds for model B: there were no significant
interaction effects between screening modality and time (P-value
range 0.15–0.95), and no significant main effect of screening
modality (P-value range 0.12–1.00) for any of the outcome scales.
Only for the VAS, there was a significant (Pp0.01) interaction
between additional diagnostic evaluation and time (model C).
Women without additional diagnostic evaluation after scheduled
screening had higher VAS scores at baseline than those undergoing
additional diagnostic procedures (83.0 vs 72.4, Pp0.01), but this
difference disappeared at T1 and T2. For the other scales, no
significant interaction effects between additional diagnostic
evaluation and time (P-value range 0.053–0.87) were seen. There
was no significant main effect of additional diagnostic evaluation
(P-value range 0.13–0.96) for any of the outcome scales.
Pain, discomfort and anxiety during different screening
modalities
Of the women who underwent a screening mammography, 21.1%
described pain intensity as ‘quite’ and 9.0% as ‘very’ (Table 3).
Table 1 Baseline characteristics of participating women at T0 according to risk category, screening modality and additional diagnostic evaluation after
screening
Risk category (n¼329) Screening modality (n¼329)
Additional
evaluation (n¼288)
Total
(n¼329)
50–85%
(n¼35)
30–50%
(n¼186)
15–30%
(n¼108)
CBE
(n¼163)
CBE+mammography
+MRI (n¼166)
Yes
(n¼21)
w
No
(n¼267)
Age (years)
Mean (s.d.) 40.9 (8.9) 41.3 (11.0) 41.4 (8.8) 40.0 (8.4) 41.1 (9.3) 40.8 (8.6) 44.5 (8.7) 40.9 (8.9)
z
Marital status (%)
Married/registered partnership 75.5 77.1 77.7 71.3 75.2 75.9 76.2 75.4
Never married 16.8 22.9 13.6 20.4 14.9 18.7 9.5 17.0
Divorced/widowed 7.6 0 8.7 8.3 9.9 5.4 14.3 7.6
Living status (%)
Living single 10.3 11.8 8.2 13.5 10.6 10.0 14.3 10.9
Living together 89.7 88.2 91.8 86.5 89.4 90.0 85.7 89.1
Parity (%)
Yes 71.7 60.0 74.7 70.4 70.6 72.9 85.7 70.7
No 28.3 40.0 25.3 29.6 29.4 27.1 14.3 29.3
Educational level (%)
Low 37.0 45.2 37.6 33.3 45.6 28.7* 31.6 36.6
Intermediate 35.0 25.8 34.1 39.6 31.3 38.7 31.6 36.1
High 27.9 29.0 28.2 27.1 23.1 32.7 36.8 27.3
Employment status: paid job (%)
Yes 73.7 65.7 74.1 75.7 74.1 73.3 66.7 75.4
No 26.3 34.3 25.9 24.3 25.9 26.7 33.3 24.6
Number of years adhering to regular surveillance
Mean (s.d) 5.4 (4.6) 3.0 (1.7) 5.6 (4.6) 5.8 (5.1)* 5.9 (5.1) 4.9 (4.1)
z 7.3 (6.0) 5.3 (4.7)
Frequency of breast self-examination (%)
At least once a week 13.5 35.3 10.4 12.0* 12.5 14.5 28.6 11.5
Approximately once a month 57.2 58.8 58.5 54.6 57.5 57.0 52.4 57.6
Approximately once every 3/6/12 months 19.4 5.9 21.9 19.4 18.1 20.6 9.5 21.0
Never 9.8 0 9.3 13.9 11.9 7.9 9.5 9.9
Benign breast diseases in the past (%)
Yes 38.8 14.3 41.8 41.7* 36.0 41.6 71.4 36.0*
No 61.2 85.7 58.2 58.3 64.0 58.4 28.6 64.0
Diagnosis of different type(s) of cancer in the past (%)
Yes 4.0 5.7 4.3 2.8 3.7 4.2 4.8 4.2
No 96.0 94.3 95.7 97.2 96.3 95.8 95.2 95.8
Mother and/or sister(s) affected with breast cancer (%)
Yes 88.6 69.7 93.5 86.0* 93.2 84.1* 95.2 87.8
No 11.4 30.3 6.5 14.0 6.8 15.9 4.8 12.2
CBE¼clinical breast examination; MRI¼magnetic resonance imaging.
*P-value p0.01.
wEight women with additional diagnostic evaluation were excluded from the analyses,
because they were still waiting for the results.
zP-value p0.10.
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lAlso 12% of the women reported the MRI to be painful. A large
proportion of the women experienced any discomfort during
mammography (69.2%) and MRI (45.3%). Anxiety was mainly
experienced during MRI, with 10.2% of the total describing anxiety
intensity as ‘quite’ to ‘very’.
DISCUSSION
Intensive surveillance in women at high risk for breast cancer due
to a familial or genetic predisposition is increasing. As its
effectiveness is yet uncertain, it is important to pay attention to
possible unfavourable side effects on health-related quality of life
and distress, which may arise from the screening process. As far as
we know, no studies had been performed before to investigate the
short-term effects of intensive surveillance on health-related
quality of life in high-risk women. This study showed that
screening women at increased risk for breast cancer, as performed
in this study by biannual CBE and annual mammography and
MRI, did not have a relevant impact on generic health-related
quality of life. Most of the women in our study underwent MRI for
the first time.
The results do not provide evidence for a distress-raising effect
of screening. The mean SOM scale scores and role-emotional and
mental health scores of the SF-36 at 2 months prior and 1–4 weeks
after screening did not show any significant difference. There are
several possible explanations for this result. First, various coping
processes can generate and sustain positive psychological states in
the context of highly stressful circumstances, thereby minimizing
or avoiding the adverse mental and physical health effects of
distress (Folkman, 1997). Second, opting for regular screening may
give women the feeling that they do everything they can to handle
their risk of getting breast cancer, eliminating possible distress-
raising effects of screening. Third, the SF-36 was not administered
at the day of the screening tests, when distress levels could be
elevated. Instead, pre- and postscreening measurement took place
2 months before and 1–4 weeks after screening. Fourth, most of
the women adhered to regular surveillance already for a longer
time, which may have lowered distress levels. A fifth explanation
relates to the method of measuring distress using the SOM scale
and the role-emotional and mental health scale of the SF-36, which
may be too general. The use of a specific measure of psychological
consequences of breast cancer screening could provide additional
insight (Cockburn et al, 1992, 1994).
Interestingly, it appeared that our study population showed
significantly better generic health-related quality of life scores (SF-
36, EQ-5D utility and SOM scale) as compared to the age-/sex-
adjusted reference scores. It seems that high-risk women who
choose for regular screening have a better health status than
women from the general population. Most of the women opt for
intensive surveillance voluntarily, and this may result in a selection
of healthy and well-coping women. This was also seen in the
Rotterdam screening trial for prostate cancer, where health status
among the voluntary attenders was better than among the general
Table 2 Observed SF-36, EQ-5D and SOM scale (SCL-90) scores (mean values and 25
th–75th percentile score intervals) of participating women at T0,
T1 and T2; comparison with (age-/sex-adjusted) reference scores
T0 (n¼329):
mean
(25th–75th
percentile)
T1 (n¼316):
mean
(25th–75th
percentile)
T2 (n¼288):
mean
(25th–75th
percentile)
Reference
scores SF-36:
Dutch general
population
a
Reference
scores SF-36:
USA general
population
b
Reference
scores EQ-5D
c
and
SOM scale
d
SF-36 (score 100–0)
Physical functioning 89.9 (85.0–100.0) — 89.4 (85.0–100.0) 86.3* 86.1*
Role – physical 85.7 (100.0–100.0) — 84.1 (100.0–100.0) 77.6* 82.8
Bodily pain 82.4 (72.0–100.0) — 83.0 (72.0–100.0) 72.8* 75.0*
General health
perceptions
76.4 (67.0–92.0) — 77.3 (67.0–92.0) 72.2* 72.7*
Vitality 67.1 (55.0–80.0) — 68.9 (55.0–80.0) 64.8 59.3*
Social functioning 87.7 (75.0–100.0) — 87.9 (75.0–100.0) 83.5* 83.0*
Role – emotional 85.2 (100.0–100.0) — 88.1 (100.0–100.0) 80.1
w 81.2
w
Mental health 76.8 (68.0–88.0) — 77.7 (68.0–88.0) 74.4
w 73.4*
SF-36 summary scores
Physical component
summary
52.5 (49.8–57.7) — 52.3 (49.2–57.7) 50.0* 50.7*
Mental component
summary
51.2 (48.3–57.8) — 52.2 (48.6–58.0) 50.1 49.1*
EQ-5D
Utility score (score 1–0) 0.88 (0.80–1.00) — 0.88 (0.80–1.00) 0.85*
VAS (self-rated health today)
(score 100–0)
81.9 (73.0–90.0) 79.0 (70.0–90.0) 80.7 (70.0-90.0) 86.9*
SOM scale SCL-90
(score 12–60)
17.5 (14.0–19.0) — 17.1 (13.0–19.0) 18.7
z
SOM¼somatic subscale; SCL-90¼Symptom Checklist-90; SF-36¼Medical Outcomes Study 36-Item Short Form; VAS¼visual analogue scale.
aAge- and sex-adjusted SF-36
reference scores (women of 16–65 years of age) from the Dutch general population (Aaronson et al, 1998). Scores were assigned to the sample of participating women at T0,
based on their age at T0.
bAge- and sex-adjusted SF-36 reference scores (women of 18–64 years of age) from the USA general population (Ware et al, 1993, 1994). Scores
were assigned to the sample of participating women at T0, based on their age at T0.
cAge- and sex-adjusted EQ-5D reference scores (women of 20–69 years of age) from the
Swedish general population (Burstro ¨m, 2003). Scores were assigned to the sample of participating women at T0, based on their age at T0.
dSex-adjusted SOM scale reference
scores (women of 18–83 years of age) from the Dutch general population (Arrindell and Ettema, 1986).
*Statistically significant (P-value p0.01) difference between observed
scores of participating women at T0 and age-and sex-adjusted reference scores (one sample t-test with best value 0).
wStatistically significant (P value p0.05) difference
between observed scores of participating women at T0 and age- and sex-adjusted reference scores (one-sample t-test with test value 0).
zStatistically significant (P-value
p0.01) difference between observed scores of participating women at T0 and sex-adjusted reference scores (two independent samples t-test with unequal variances).
Breast screening and quality of life in high-risk women
AJ Rijnsburger et al
73
British Journal of Cancer (2004) 91(1), 69–76 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lpopulation (Essink-Bot et al, 1998). The difference in health status
between our study sample and the general population may partly
be due to difference in educational level. Participants in the health-
status study appeared to have a significant (P¼0.03) higher
educational level compared to Dutch women aged 15–64 years
(Statistics Netherlands, 2004). Individuals with a higher education
are more likely to undergo screening (Liu et al, 2001). Moreover,
higher levels of education are also associated with higher levels of
quality of life (Regidor et al, 1999).
Women who refrained from participation in the health-status
study all opted for intensive surveillance. They did not differ from
our study sample with respect to age and risk category.
Nevertheless, it is still possible that they differed from our study
sample with respect to health-related quality of life, but we had no
data available.
Observed VAS scores among our study sample were significantly
lower compared to the age- and sex-adjusted reference scores. This
may be caused by the fact that the labelled anchors of the Swedish
reference scores were ‘dead’ and ‘full health’, instead of ‘worst
imaginable health state’ and ‘best imaginable health state’
(Burstro ¨m, 2003).
The VAS score was the only generic health-related quality of life
score that showed a significant change over time. However, the
absolute differences between the mean VAS scores were small.
Generic health-related quality of life, as well as the impact of the
screening process on generic health-related quality of life, did not
differ between the three risk categories. These risk categories
represent the baseline objective CLTR of developing breast cancer,
based on the tables of Claus (Claus et al, 1994). In these analyses,
we did not take into account the women’s cognitive or affective
perceptions of their risk of developing breast cancer.
Relatively more women reported mammography as quite to very
painful (30.1%) compared to CBE or MRI, while a large proportion
of the women experienced any discomfort during mammography
(69.2%) and MRI (45.3%). The documented incidence of pain
associated with screening mammography varies from 1 to 62%
(Sapir et al, 2003). Patient education by trained nursing
counsellors may reduce mammography-related pain and discom-
fort (Nielsen et al, 1993). Since all mammograms in our study
sample were performed at the Erasmus MC, Daniel den Hoed
Cancer Center by extremely skilled technicians who inform and
support the women, and the majority of the women did not
undergo mammography for the first time (contrary to MRI), we
think that a lack of information with respect to pain and
discomfort experience at mammography is not the issue, rather
than the examination itself.
Anxiety was experienced by 37% of the women undergoing MRI.
Of the women participating in the MRISC study, 1.8% stopped the
study protocol because they refused another MRI or were anxious
for the MRI exam (unpublished data).
We did not investigate the impact of additional diagnostic work-
up on generic health-related quality of life during recall. There is
evidence that recall after a false-positive mammogram causes
elevated levels of anxiety and breast cancer worries, even after
receiving reassurance that all is well (Lerman et al, 1991; Cockburn
et al, 1994). More research on this item is warranted.
Besides intensive surveillance, prophylactic mastectomy is an
alternative risk reducing strategy, especially for BRCA 1/2
mutation carriers (Meijers-Heijboer et al, 2001). In the Family
Cancer Clinic of the Erasmus MC, approximately half of the
unaffected BRCA 1/2 mutation carriers opts for prophylactic
mastectomy (Meijers-Heijboer et al, 2000). However, the use and
accessibility of prophylactic surgery differs largely between
countries (Julian-Reynier et al, 2001). Results from studies on
the impact of prophylactic mastectomy on generic health-related
quality of life are not available in the literature. Utility ratings of
prophylactic oophorectomy and mastectomy seem low, although
reduction in anxiety was not taken into account (Grann et al,
1998). Lodder et al (2002) showed that women opting for
prophylactic mastectomy had significant higher distress levels
than mutation carriers who opted for surveillance, but their
distress levels decreased significantly 6 months or longer after
surgery, possibly due to the significant risk reduction of
developing breast cancer.
We conclude that the screening process does not have an
unfavourable impact on short-term generic health-related quality
of life and general distress in women at high risk for breast cancer.
In this study, high-risk women who opted for regular breast cancer
screening had a better health status than women from the general
population, which may partly be due to difference in educational
level.
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Health-status measures
The SF-36 (Ware and Sherbourne, 1992) includes eight multiitem
scales: physical functioning, role limitations due to physical
problems (role-physical), bodily pain, general health perceptions,
vitality, social functioning, role limitations due to emotional
problems (role-emotional) and mental health. It produces a health
profile with scores between 0 and 100 for each dimension, with
higher scores indicating a better health status (Ware et al, 1993).
Two summary scale scores can be computed that aggregate the
eight scales: the physical component summary and the mental
component summary. These summary scores have a mean score of
50 (s.d.¼10) for the general United States population (Ware et al,
1994). We used a validated Dutch version of the SF-36 (Aaronson
et al, 1992, 1998) with a time frame (reference period) of 1 week.
The EQ-5D (Brooks, 1996) is a five-item self-classifier with
regard to mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Each item has three levels: no problems (1),
some problems (2) and extreme problems (3). The derived health
state descriptions can be linked directly to empirical valuations of
health states by the general population, generating utilities that can
be used in the calculation of quality adjusted life years
(Dolan, 1997). The EQ-5D also contains a VAS on which
respondents rate their own health between 0 (labelled as ‘worst
imaginable health state’) to 100 (labelled as ‘best imaginable health
state’). For this study, the standard Dutch EQ-5D was used
(EuroQol, 1996).
The SCL-90 (Derogatis et al, 1973; Derogatis, 1977) is a self-
report symptom inventory for the measurement of psychological
distress and psychopathology. The 12-item SOM scale measures
complaints about general physical dysfunction as a result of
psychogenic or stress-related problems. However, the possibility of
actual physical disabilities has to be taken into account. Each item
has five levels: not at all (1), a little (2), quite (3), very (4) and
extremely (5), providing a total scale score between 12 and 60.
The screen-specific items are self-developed items on experi-
ences during the different screening tests. They are based on items
developed to grade pain and physical discomfort of various
prostate cancer screening tests (Essink-Bot et al, 1998). Women
were retrospectively (at T2) asked to grade pain, discomfort and
anxiety, experienced during CBE, mammography and MRI,
respectively. Each item has answer categories on a 4-point Likert
scale with labelled end points ‘not’ and ‘very’.
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